Press release

For media and investors only

Issued: 3 September 2024, London UK

GSK aims to redefine the future of respiratory medicine at the European Respiratory Society International Congress

- First presentation of SWIFT-1 and SWIFT-2 phase III trial data for ultra-long-acting biologic depemokimab in severe asthma
- GSK aspires to change the course of disease, reversing disease damage and, for patients with asthma, achieve long-term clinical remission
- 56 abstracts to advance scientific understanding and support GSK's ambition to improve the lives of millions of people with respiratory conditions

GSK plc (LSE/NYSE: GSK) will share latest research findings from across its diverse respiratory portfolio of innovative therapies, including targeted biologics, vaccines and inhaled medicines, at the 2024 European Respiratory Society (ERS) International Congress in Vienna (7-11 September). The research, including three late-breaking abstracts, demonstrates the company's commitment and ongoing ambition to redefine the future of respiratory medicine and deliver the next generation standard of care for millions of people affected by respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), refractory chronic cough and respiratory syncytial virus (RSV).

GSK's ambitious goals build on decades of expertise, research and collaboration as the company works to reduce the global burden of respiratory diseases by providing protection from infections and the associated complications, preventing exacerbations, cumulative lung damage and disease progression while providing optimal treatment of symptoms. This means aiming for clinical remission for as many people with asthma as possible at the earliest point in their disease journey to protect their future health.

Study results from SWIFT-1 and SWIFT-2

The first presentation of the positive results from SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterised by blood eosinophil count, will be shared in a late-breaking alert session on Monday, 9 September at 3.45 CEST. Depemokimab is the first ultra-long-acting biologic to be evaluated in phase III trials with a binding affinity and high potency for interleukin-5 (IL-5), enabling six-month dosing intervals for patients with severe asthma. Long-acting treatments that combine an extended half-life with high potency have the potential to offer sustained suppression of the underlying drivers that contribute to disease outcomes and progression for extended periods.

Clinical remission in severe asthma

Data presented at ERS for *Nucala* (mepolizumab) builds on the already robust and expansive data on the role of targeting IL-5. Aiming for clinical remission is a critical treatment goal for patients with severe asthma and type 2 inflammation. Further data on clinical remission provides additional insights into evidence-based management strategies with research looking at characteristics that influence clinical remission and also the role of biologic therapy in achieving this treatment goal. Additional research for *Trelegy* (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) will also look at clinical remission as a treatment goal in in other types and severities of asthma.

Research on COPD exacerbations

A post-hoc analysis from METREX and METREO will be presented, which shows the effect of *Nucala* in the trial participants with or without chronic bronchitis. A poster presentation of the study design of MATINEE, the third clinical study of *Nucala* in COPD, will be presented. MATINEE recruited COPD patients with broad clinical presentations of chronic bronchitis and/or emphysema, along with evidence of type 2 inflammation characterised by blood eosinophil count and builds on existing data for *Nucala*. Research being presented at ERS also includes

the latest evidence to support the use of *Trelegy* in COPD and more specifically advancing research of disease stability as a realistic treatment goal.

Key abstracts presented at ERS
Encouraging new data will be presented from GSK's portfolio that could transform outcomes for patients living with respiratory disease.

Abstract Name	Presenter	Presentation Details
Depemokimab efficacy/safety in patients with asthma on medium/high-dose ICS: the Phase IIIA randomised SWIFT-1/2 studies	D. Jackson	Oral presentation Session 356 #RCT3718
Depemokimab PK/PD in the 52-week randomised double-blind multicentre Phase III SWIFT-1 trial	I. Pavord	Oral presentation Session 345 #OA3647
Mepolizumab in patients with asthma and features of COPD: a MENSA/MUSCA post hoc analysis	I. Pavord	Poster presentation Session 415 #PA4492
Mepolizumab response in patients with COPD and an eosinophilic phenotype with/without chronic bronchitis (CB): a METREX/METREO post hoc analysis	C. Vogelmeier	Poster presentation Session 460 #PA4783
Clinical trial design of biologic therapies in COPD: MATINEE study of mepolizumab	I. Pavord	Poster presentation Session 460 #PA4789
Real-world assessment of clinical remission in asthma with biologics	P. Howarth	Poster presentation Session 225 #PA2182
Clinical characteristics impacting clinical remission attainment in REALITI-A	G. Canonica	Poster presentation Session 133 #PA1200
Assessment of the components of clinical remission with moderate–severe asthma after 24–52 weeks of treatment: CAPTAIN post hoc analysis	I. Pavord	Poster presentation Session 133 #PA1198
Characteristics of patients meeting the components of clinical remission: CAPTAIN post hoc analysis	S. Noorduyn	Poster presentation Session 133 #PA1197
Impact of varying lung function threshold on clinical remission in asthma with FF/UMEC/VI: CAPTAIN post hoc analysis	I. Pavord	Poster presentation Session 133 #PA1199
Towards disease stability in COPD management: patient perspectives	M. Brooke	Poster presentation Session 132 #PA1171
Impact of varying health status thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis	D. Halpin	Poster presentation Session 132 #PA1173
Impact of varying lung function thresholds on disease stability in COPD with FF/UMEC/VI: IMPACT post hoc analysis	D. Halpin	Oral presentation Session 443 #OA4653

About GSK in respiratory
GSK continues to build on decades of pioneering work to deliver more ambitious treatment goals, develop the next generation standard of care, and redefine the future of respiratory medicine for hundreds of millions of people with respiratory diseases. With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics and

inhaled medicines, we are focused on improving outcomes and the lives of people living with all types of asthma and COPD along with less understood refractory chronic cough or rarer conditions like systemic sclerosis with interstitial lung disease. GSK is harnessing the latest science and technology with the aim to modify underlying disease dysfunction and prevent disease progression.

About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

GSK enquiries

Media:	Tim Foley	+44 (0) 20 8047 5502	(London)
	Dan Smith	+44 (0) 20 8047 5502	(London)
	Kathleen Quinn	+1 202 603 5003	(Washington DC)
	Lyndsay Meyer	+1 202 302 4595	(Washington DC)
	Alison Hunt	+1 540 742 3391	(Washington DC)
Investor Relations:	Nick Stone	+44 (0) 7717 618834	(London)
	James Dodwell	+44 (0) 20 8047 2406	(London)
	Mick Readey	+44 (0) 7990 339653	(London)
	Steph Mountifield	+44 (0) 7796 707505	(London)
	Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
	Frannie DeFranco	+1 215 751 4855	(Philadelphia)

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q2 Results for 2024.

Registered in England & Wales:
No. 3888792

Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS